DOP77 The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's disease

Knyazev, Oleg; Каграманова, А В; Lishchinskaya, A; Zvyaglova, Mariya; Kulakov, Dmitriy; Парфенов, А И

doi:10.1093/ecco-jcc/jjy222.111

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to treat by MSCs or MSCs plus fibrin glue, some studies combined MSCs with other traditional medicine to treat fistulas. Knyazev et al [ 66 ] performed a clinical trial to compare the effectiveness of combined therapy (local and systemic administration) of BSCs, BSCs (local administration), and certolizumab pegol (CZP) in CD fistulas. They demonstrated that combined cell and anti-cytokine therapy with CZP of CD with perianal lesions promotes more frequent and prolonged closure of simple fistulas, compared with BSCs monotherapy and CZP monotherapy.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials

Wang

Jiang²,

Zhang

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Perianal fistulas, characterised as granulomatous inflammation of fistulas around the anal canal, are associated with significant morbidity resulting in a negative impact on quality of life and a tremendous burden to the healthcare system. Treatment of anal fistulas usually consists of anal surgery; however, results of closure rates are not satisfactory especially with complex perianal fistulas, after which many patients may suffer from anal incontinence. Recently, the administration of mesenchymal stem cells (MSCs) has shown promising efficacy. Herein, we aim to explore whether MSCs are effective for complex perianal fistulas and if they have either short-term, medium-term, long-term or over-long-term efficacy. Additionally, we want to elucidate whether factors such as drug dosage, MSC source, cell type, and disease aetiology influence treatment efficacy. Main body of the abstract We searched four online databases and analysed data based on information within the clinical trials registry. The outcomes of eligible trials were analysed with Review Manager 5.4.1. Relative risk and related 95% confidence interval were calculated to compare the effect between the MSCs and control groups. In addition, the Cochrane risk of bias tool was applied to evaluate the bias risk of eligible studies. Meta-analyses showed that therapy with MSCs was superior to conventional treatment for complex perianal fistulas in short-, long- and over-long-term follow-up phases. However, there was no statistical difference in treatment efficacy in the medium term between the two methods. Subgroup meta-analyses showed factors including cell type, cell source and cell dosage were superior compared to the control, but there was no significant difference between different experimental groups of those factors. Besides, local MSCs therapy has shown more promising results for fistulas as a result of Crohn’s Disease (CD). Although we tend to maintain that MSCs therapy is effective for cryptoglandular fistulas equally, more studies are needed to confirm this conclusion in the future. Short conclusion MSCs Transplantation could be a new therapeutic method for complex perianal fistulas of both cryptoglandular and CD origin showing high efficacy in the short-term to over-long-term phases, as well as high efficacy in sustained healing. The difference in cell types, cell sources and cell dosages did not influence MSCs’ efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%